First patient received ZX-4081 treatment in the phase 1 trial
Date / 2022.01.06
On January 4, 2022, Zenshine Pharma announced that ZX-4081 was dosed to the first patient  in the US. First-in-human study of ZX-4081(NCT05118841) is an open-label, multicenter, dose escalation and dose expansion study to investigate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of ZX-4081 administered orally (PO) twice daily (BID) in 28-day cycles in patients with advanced solid tumors.

About ZX-4081

ZX-4081 is a potent and highly selective PI3Kγ inhibitor and the only other PI3Kγ selective inhibitor in the clinical trial  IND approval of ZX-4081 was granted by FDA in July 2021. Recent studies found that PI3Kγ is a molecular switch that governs immune suppression and promotes immunosuppressive myeloid cell polarization during tumor growth and metastasis. Through in vitro and in vivo preclinical studies at Zenshine, ZX-4081 showed the ability of tumor growth inhibition by reprogramming tumor microenvironment via impairing PI3Kγ-AKT-mediated macrophage polarization to enhance anti-cancer immunity. It has tremendous potential to overcome resistance to immune checkpoint inhibitors as combination therapies and provides an innovative treatment to under-treated patients. 

About Zenshine Pharma

Zenshine Pharma is a clinical stage biopharmaceutical company, focused on small molecule therapeutics in the areas of cancer, viral infection and inflammation. Our mission is to apply the best science to serve patients. Zenshine leverages the team’s extensive expertise and experience in developing proprietary chemical entities with well-defined differentiation to benefit the patients. By targeting key biological pathways to disrupt virus replication, directly block tumor growth and enhance anti-tumor immune responses, Zenshine commits to providing bench-side to bed-side solutions and delivering the best-in-class or first-in-class therapeutics.

Back to list